Konverge Plus

Olmesartan medoxomil, amlodipine, and hydrochlorothiazide, the active ingredients in Konverge Plus, are an angiotensin II receptor blocker, a calcium‑channel blocker, and a thiazide diuretic respectively, presented as an oral tablet for systemic use. This fixed‑dose combination is prescribed to lower elevated blood pressure and reduce cardiovascular risk in adult patients with hypertension.

GNH USA supplies Konverge Plus as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality standards and supporting reliable procurement for global healthcare systems.

Konverge Plus, a fixed‑dose antihypertensive combination, is employed to manage elevated blood pressure across several clinical scenarios.

- Hypertension: reduces systolic and diastolic blood pressure to target levels. - Essential hypertension: provides consistent blood pressure control when monotherapy is insufficient. - Resistant hypertension: offers a multi‑mechanistic approach for patients uncontrolled on single agents. - Hypertension with peripheral edema: amlodipine‑induced edema is mitigated by the diuretic component. - Hypertension in patients with diabetes: aids blood pressure reduction while minimizing metabolic impact.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or lower legs. - Flushing: transient warmth and redness of the skin. - Fatigue: general feeling of tiredness. - Increased urination: due to diuretic effect.

Serious or Rare Side Effects: - Severe hypotension: markedly low blood pressure causing fainting. - Electrolyte disturbances: hyperkalemia, hyponatremia, or hypokalemia. - Acute renal impairment: sudden decline in kidney function. - Angio‑edema: rapid swelling of face, lips, or throat. - Liver dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or severe hypersensitivity.

Before initiating therapy, consider the following precautions: - Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Renal function assessment: evaluate creatinine and eGFR, especially in patients with existing kidney disease. - Electrolyte balance: monitor serum potassium and sodium periodically. - Hepatic impairment: use with caution in moderate to severe liver disease. - Pregnancy and lactation: avoid unless clearly indicated; discuss alternatives with the prescriber. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Konverge Plus may interact with several medications.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - ACE inhibitors or aliskiren combined with olmesartan: increased risk of renal dysfunction. - Lithium: elevated lithium concentrations leading to toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may attenuate antihypertensive effect. - Strong CYP3A4 inhibitors (e.g., erythromycin): increase amlodipine plasma levels. - Strong CYP3A4 inducers (e.g., rifampin): reduce amlodipine efficacy. - Other antihypertensives: additive blood pressure lowering, requiring dose adjustments.